Biocept

Biocept EBIT CAGR 10Y

Delisted

The EBIT CAGR (10 Year) of Biocept (BIOC) as of Nov 3, 2026 is 11.78 %. In the previous year, EBIT CAGR (10 Year) was 11.78 % — a change of 0.00% (lower).

EBIT CAGR 10Y

11.78 %

YoY

0.00%

Last updated:

EBIT CAGR (10 Year) of Biocept is 2022 11.78 % . EBIT CAGR (10 Year) of Biocept was 2021 11.78 % . It decreases by 0.00% lower compared to the previous year.

The Biocept EBIT CAGR 10Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 10Y
Date
EBIT CAGR 10Y
Jan 1, 2015
11.78 USD
Jan 1, 2016
11.78 USD
Jan 1, 2017
11.78 USD
Jan 1, 2018
11.78 USD
Jan 1, 2019
11.78 USD
Jan 1, 2020
11.78 USD
Jan 1, 2021
11.78 USD
Jan 1, 2022
11.78 USD
The Biocept EBIT CAGR 10Y history
YEAREBIT CAGR 10YYoY
11.78 %0.00%
11.78 %0.00%
11.78 %0.00%
11.78 %0.00%
11.78 %0.00%
11.78 %0.00%
11.78 %0.00%
11.78 %0.00%
11.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

EBIT CAGR (10 Year) of Biocept is 11.78 % in 2022.

On Eulerpool you can find the complete historical development of EBIT CAGR (10 Year) Biocept since 2006 – with annual values, charts, and detailed analysis.

The 10-year EBIT CAGR shows the long-term compound annual growth rate of operating earnings.

To evaluate EBIT CAGR (10 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (10 Year).

EBIT CAGR (10 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (10 Year)'s Biocept historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biocept

All Key Metrics — Biocept